David Sinclair· PhD
Intravenous FOXO3-enhanced cells outperformed regular stem cells in decelerating multi-organ aging clocks demonstrating their potential as a clinical cell therapy to combat aging and related health issues
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Intravenous FOXO3-enhanced cells outperformed regular stem cells in decelerating multi-organ aging clocks demonstrating their potential as a clinical cell therapy to combat aging and related health issues
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
demonstrating their potential as a clinical cell therapy to combat aging and related health issues